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The principal application of Factor IX concentrates is for hemo-
philia B patients threatened with circulatory overloading when severe
hemorrhages or surgical treatment make it necessary to replace the
missing coagulation factor by whole blood or plasma transfusion.
Unlike the preparation of a Factor VIII concentrate, which can
be done very simply and efficiently with the cryoprecipitation pro-
cedure according to Pool (r), the puriffcation of Factor IX for
clinical use is rather complicated. With plasma as starting material,
the result of the usual methods is not onlv the concentration of Factor
IX on a protein basis, but also, due to tireir similar adsorption prop-
erties, the purification of the other factors of the so-called prothrombin
complex. Consequently, this type of preparation is useful not only
for patients with hemophilia B, but also for those with a deffciency
of the complex of Factors II, VII, IX and X, such as occur in severe
liver function disturbances, real vitamin K deffciency,.and, last but not
least, th6 relative vitamin K deffciency induced by treatment with
coumarin.
In situations where there is no time to wait for the efiect of
vitamin K administration*, such as intracranial hemorrhage during
* Intravenously administgred vitamin K, takes a minimum of 8 hr to provide
a safe level of the prothrombin complex. 
-
t'
anticoagulant treatment (z), or when hemorrhagic_ complications
must be prevented or treated, as in cases of severe disturbances of
liver funcltion, the administration of puriffed Factors II, VII, IX and
X may be indicated. Lastly, severely disturbed hemostasis, seen in
"orrg"nit"l 
deffciencies of Factors II, VII or X individually, may also
be in indication. In practice, however, the main use of the concen-
trate is for the substitution treatment in hemophilia B to combat
serious hemorrhagic complications, which is the main subject of this
report.
In Leiden, during the period between 196o and 1967, eight pa-
tients sufiering from hetnophiliu B (three sevele, one moderate, and
four mild) wJre given substitution therapy with the French prepara-
tion P.P.s.B. ( Prothrombin-Proconvertin-stuart factor-antihemophilic
factor B), obtained from the Centre National de Transfusion San-
guine in Paris (3, 4, 5 ). For the evaluation of the therapeutic results
Jf soch treatment, a good method for the determination of Factor IX
is indispensable. Up to 1964., we used a one-stage method 
_having a
standari deviation of at least rcTo of the values obtained. By modi-
ffcation of the one-stage method according to Hardisty and Mac-
pherson (6) and the use of a semiautomatic reading=of the c-oagulation
ii-"r, Veltkamp (7) was able to reduce the coefficient of variation
to 6%o-7Vo. Using this reliable method of determination, we obtained
values for the u"tiuity of P.P.s.B. in oitro which showed good agree-
ment with those given by the manufacturer. The administration of
P.P.S.B. to patients showed that the in oiao characteristics of this puri-
ffed Factoi IX agreed closely with those of Factor IX in normal
plasma. The biological halflife amounted to approximately zo hr.
fuith utt equilibration halflife of several minutes, half of the amount
had disappeared from the intravascular spaca In_ patients retaining
,o*" 
""ful"ity 
to produce Factor IX (the mild and moderate Wp"t),
this production was not suppressed by- the substitution treatment'
Tirese data made it possible to formulate a general dosage scheme
for the daily required quantities of Factor IX, expressed ,as the
equivalent oi the activity of H ml net 
-plasma (i.e., ACD excluded)
urid ud-ittistered as a constant drip infusion, as follows:
H : I T X P X L
in which H - net plasma equivalent in ml; P - plasma- volume in
liters; L: desired iise of the blood level in per cent; the constant
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o . 6 g 3 X 2 4 X 2 \ r o o o
, in which o.693: ln z;rz is derived from 20 X 1oo
z4: d:Utratlon of the infusion in hours; z - multipllcation factor for
Factor lX Concentrates s
calculation of the actual distribution space of Factor IX, and zo :
biological half-life of Factor IX in houri
- T" dosage for patients of the mild or moderate types is calcu-lated by subtracting the pretransfusion value from the desired level.
Table r shows the desired Factor IX concentration in the case of
severe hemorrhage or surgical treatment, as well as the quantity of
plasma required for an arbitrarily chosen hemophilia B paiient. Fig.
r gives an example of substitution treatment with the French
EqutvAL- FRESH PLAST{A (A C D EXCL.I
Fig. l. Doto obtoined uring substitr,,"" ,tn"rl'orrtto",ll*'; ,;;;;:;,l9-yeoi-old mole; Foctor lX < I o/o of normol; operotion for tolipes equinus.
P.P.S.B. in a patient suffering from severe hemophilia B. After a
spontaneous intramuscular hemorrh]ge in the calf of his left leg, a
talipes equinus developed for which the boy was treated surgiclally
under !.1.S.8. protection in 1966. The postoperative 
"orrrri 
*u,
uneventful.
In the other seven cases P.P.s.B. gave excellent results. The hemo-
static effect was completely_ satisfactory. It is very important to keep
in mind that in clinical conditions in wlich the turnovei rate of Factor
IX is increased, as in cases with a general acceleration of catabolism(e.g., fever, hyperthyroidism,' and anemia), the requirement can rise
to three times the normal value.(4).
The theoretical data have little practicar varue as long as concen-
trated Factor rX preparations remain as scarce and difficilt to obtain
FACTOR lX  ACl lY l lY  I  tog .  rco t r  I
FAcIoR [  (Hl,  v[  lG---1, .nd x (Hl Acnvt lv
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Toble l. Dosoge Scheme for Adult Hemophilio B Potient
(Foctor D( - 0o/o of Normol, Body Weight 70 kg, Plosrno Volume 2.5 liters)
ml Net Plosmo
In v ivo Concentrot ion
Obtoined o/o
Looding dose
Doily dose, (constont
drip infusion)
lst-4th doy
5th- lOth  doy
I  l th - l4 th  doy
Totol dose
2000
r 700
1275
850
2000
40-50
40-50
30-40
20-30
as they still are at present. The French Production can only meet a
small part of the demand within France, and the same holds for
England. About the general availability of the American concentrates
we have no information. Because of the urgent need, small production
has been undertaken in The Netherlands according to the method
of Soulier et al. (8), and the DEAE-adsorPtion method modified after
Mel in (9) .
Toble 2. Prothrornbql
Foctor | | Foctors Vl l /X Foctor lX
ln vitro yield o/o
ln vivo yield o/o
In general, it is impossible for the smaller laboratories to adopt
the method of Soulier et al., because this Procedure calls for the use
of EDTA blood, and packed cells cannot be used without a special
preliminary treatment. Furthermore, the method is tejchnically rather
complicated and laborious. The latter holds even rnore strongly for
the method of Bidwell et al. (ro). As a consequence, there is a
great deal of interest in a procedure for the puriffcation of Factor IX
from ordinary blood bank material, i.e., citrated blood. This would
leave all the packed cells for clinical use without extra processing
and also permit the production of cryoprecipitate and albumin and
gamma globulin preparations.
In our laboratory we have solved this problem in the following
way: if the supematant citrated plasma remaining after cryoprecipita-
tion according to Pool is used, the prothrombin complex cannot be
adsorbed with calcium phosphate or barium sulfate. But with a well-
72
+-20
r 0 650
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chosen aluminum hydroxide preparatiog, this complex can be removed
virtually completely from the plasma, leaving the albumin and gamma
globulins in the plasma for further isolation.
Puriffcation of Factors II, VII, IX and X of 5 to r5 times, based
on the protein conten! is adequate for the clinician's purposes. Thus
a higher yield for coagulation activity and a simpler preparation
method are possible, compared to concentrates more highly puriffed.
After adsorption we elute directly with a phosphate solution
CITRATED PLASMA
CRVOPRECIPITATIO N
./
a ,,ffi,
\<, S-3 Ar (oH)3\ - - t  F=1k#\ F,
ADSoRPTTot 
\ gl pHospr{ArE-EDTA
E_#\
A R T I  F I C I A L  K I D N E Y
,R
l ; ? lrneeze-onvw
PROTHROM BAL
Fig., 2, Diogrom of piocedure of preporotion of Prothrombol.
ELUTION
DIA  LYS IS
FILTRATION
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factor
fresh
lX infused; as 
.equivalent
ptasme, ACD exctuded
1  2  3  I  5  6 d a y s
Fis. 3. Results of infusion of Prothrombol;
potient GB 318/66; 2O-yeor-old mole; Foctor lX I 1o/o
of normol; plosmc volume 1.84 l i ters.
containing sodium EDTA to eliminatir by chelatiori the calcium
that might promote the formation of thrombin. Since the op
phosphate concentration is too high to permit administration to a
patient, dialysis is applied. We have found that the simplest and most
efiective way to perform dialysis is with a simpliffed artiffcial
,according to Kiil. After several hours of dialysis in a sterile,
system, the phosphate and EDTA concentrations are so low
after a precautionar), passage over bacteria fflters, the preparation
suitable for administration. A satisfactory product can be obtained
with this method in about B hr. The resulting preparation, which we
call Prothrombal, is then freeze-dried. The entire procedure is carried
out under aseptic conditions, which we consider to be an important
6/c
100
2
1
mt/hr.
800
100
1 0
I
L*
%
100
80
Factor lX Concen"trates g
fac to r  I I  ac t i v i t y  R.
o+ us ing  Pat ien t ' s  P tesma
F{  us ing  ar t i f i c ia t  reagent
-*R\==..=_g=,,0",
factor II infuled ; as equivatent to fresh ptasm. ACD exctuded
[3 using patient's plasma
12 using artificial reagent
1
mt/hr
600
20
1 0
8
4
2
200
0
7 daysr
Fig.4. Results of infusion of Prothrombol; potient
GK 314/68; 26-yeor-old mole; Foctor l l  opproximotely 1o/o
of normol; plosmo volume 3 l i ters.
condition to insure the absence of pyrogens.
Table z shows the results of activity determinations in Ditro a\d
in oioo. If further purification is desired, this can be easily achieved
by washing the aluminum hydroxide after adsorption with a solution
of NaCl or, more efiectively, of citrate or EDTA.
We have found, however, that prolongation of the adsorption
time causes not only further activation of Factors VII and IX, but
also denaturation. The resulting lability, especially of Factor IX, is
expressed in a loss of activity during the procedure following elution,
e.g., during dialysis. Fig. z gives a schematic representation of the
procedure. We apply strict standards to each batch with respect to
absence of thrombin activity, toxicity in mice, pyrogenicity in rabbits,
and cardiovascular efiects in cats or dogs. So far, transfusions have
been performed in three patients with severe hemophilia B (Factor IX
less than tVo of normal). None of these patients showed undesirable
10 rrEMop.HrLrA n-Therapeutic Concentrates
2 6 1 0 1 4 1 8 2 2 2 6 3 0 3 4
nours
Fig. 5. Results of infusion of Prothrombol; potient
GK 347/68; 2O-yeor-old femole; Foctor Vl l
olosmo volume 1.9 l i ters.
reactions. Fig. S gives the data for one of these cases as illustra
showing that an activity of almost rooVo can be reached in oirso
out difficulty. Calculations based on the results of the three
philia B patients showed that the in oi,oo yield of Factor IX was
fourth of the in oitro activity of the preparation administered. The
vergence is probably related to the observation that Factor IX is
vated during adsorption, which results in an increased lability
pressed in the rapid initial drop of the level of this factor.
subsequent rate of disappearance agrees well with the value found
for other transfusions (\lz approximately zo hr). The ffnal yield
in oioo is in approximate agreement with the Factor IX yield ob-
tained with the French method (t57o to zoVo).
The results of a transfusion with our preparation in a case with a
fac to r  V l l  in fused ;  as  equ iva len t  o
fresh plasma, ACD excluded
prothrombin time
sec.
200
180
160
110
1 2 0
100
80
60
1 0
2 0
0
mt/hr
1000
800
22 26 30
Fig. 6. Results of infusion of Prothrombol; potient
GBOE I  175/68;  25-yeor-old mole;  p losmo volume obout
2.5 l i ters;  severe v i tomin K def ic iency.
congenital prothrombin deficiency are shown in Fig. 4. This patient
has a hemorrhagic diathesis entirely comparable to that of a severe
hemophiliac and resulting, among other things, in spontaneous bleed-
ing in ioints and muscles. The total quantity of prothrombin ad-
ministered corresponds to the activity of about 1.5 lite$ net plasma.
The Factor II concentration reached in this patient agrees rather well
with his plasma volume of 3 liters. After a rather blow equilibration
during the ffrst day, the disappearance rate of Factor II corresponded
to the biological halflife of about four days.
Fig. S shows the effect of the administration of our preparation
to a girl with congenital Factor VII deffciency who snfiered from
severe hemarthroses and menorrhagia. The administered dose of
600
100
200
3a 38
nours
f----l tactor YIl
m.ffil factor IX infused ; as eqoivetent to
N factorx fresh pl.:sma,AcD excl.ldld
74 tzctor Il
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Factor VII prepared from 4 liters of plasma had an in aitro vaft'
ug.""irrg *iti tt 
" 
activity of 78o-o-m1-1",t 1ot-11 
plasma'which aga:
indicates activation of Factor VII' With this dose we obtained in
nlasma volume of t.gz liters a Factor VII concentration of tgzTa t
I".-^f. The disappelrur."" curve is not distinctly biphasic; the^Facti
VII activity seems to have disappeared initially with artlz of abo-
z hr and tfiereafter with a r:-lz of about 3 hr'- - 
Lastly, Fig' 6 shows the case of a z5-year-old"man iamittef !,
"urrr" 
of chrJnic pancreatitis' He was bleeding fo9T tr: nose aI' '
gums and ,ho*"i a severe vitamin K deficiency' Administratiori :
il;; dose as that used in the foregoing case caused the prothro:-
Ui" ii*" to drop sharply to subnormal values' After infusion we '-
i"*"a the protiromb-in time to rise again before intravenous aj-
ministration of vitamin Kr. As can be seen from the figure' maxinl"
stimulation of the patient's production of the prothrombin .compl=:
L/ ui u-1" K, takes'much more time to reach safe hemostatic lere-'
In case of emergency, therefore, vitamin Kr and purified prothromb:
complex should be administered together'
SummarY
The recent availability of suitable methods for the preparatic:
of a concentrate of Factors iI, VII, IX, and X as well as data on ti'.
"ft"i""f 
applicability of these preparations have greatly improved ti-:
prognosir^;f the hernophilia B patient' The same holds for congeni:''
i, i"q.rl"a deficiencils of Factors II, VII and X' individually or 
'-
combilnation. This concentrate therefore also represents an immediat.'
lv efiective antidote for coumarin congeners' A simple method f'-:
J ^
th" pr"purution of a Factor IX concentrate is described' Packed cel'
throinbicyte suspensions' cryoprecipitate' albumin and gamma glot-
ulins can be prepared withoui any loss or difficulty from the samt
citrated blood.
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